Establishment Labs Holdings Inc. (NASDAQ:ESTA – Get Rating) was the recipient of a large growth in short interest in the month of May. As of May 31st, there was short interest totalling 1,550,000 shares, a growth of 26.0% from the May 15th total of 1,230,000 shares. Based on an average daily volume of 216,300 shares, the days-to-cover ratio is currently 7.2 days. Approximately 7.5% of the company’s stock are short sold.
Several equities analysts have recently weighed in on ESTA shares. The Goldman Sachs Group decreased their price objective on Establishment Labs from $78.00 to $67.00 and set a “neutral” rating for the company in a report on Monday, March 21st. Cowen lifted their price target on Establishment Labs from $95.00 to $125.00 in a report on Friday, April 22nd. Cowen lifted their price target on Establishment Labs from $95.00 to $125.00 in a report on Friday, April 22nd. Finally, BTIG Research lifted their price target on Establishment Labs from $95.00 to $110.00 and gave the stock a “buy” rating in a report on Friday, April 22nd.
Shares of NASDAQ:ESTA opened at $52.64 on Friday. Establishment Labs has a 12-month low of $46.93 and a 12-month high of $93.80. The stock has a market cap of $1.27 billion, a PE ratio of -31.77 and a beta of 1.09. The business has a 50 day moving average of $64.90 and a 200-day moving average of $61.86. The company has a quick ratio of 2.23, a current ratio of 3.01 and a debt-to-equity ratio of 1.10.
Establishment Labs (NASDAQ:ESTA – Get Rating) last issued its quarterly earnings data on Monday, May 9th. The company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.18. Establishment Labs had a negative return on equity of 70.10% and a negative net margin of 29.77%. During the same period last year, the business posted ($0.29) EPS. Equities research analysts expect that Establishment Labs will post -1.32 earnings per share for the current year.
In related news, major shareholder Jw Asset Management, Llc acquired 10,000 shares of the firm’s stock in a transaction dated Monday, May 9th. The stock was bought at an average price of $57.52 per share, for a total transaction of $575,200.00. Following the acquisition, the insider now directly owns 3,187,485 shares of the company’s stock, valued at $183,344,137.20. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders acquired a total of 50,000 shares of company stock worth $3,299,700 in the last three months. Company insiders own 13.08% of the company’s stock.
Institutional investors have recently modified their holdings of the business. Schonfeld Strategic Advisors LLC raised its stake in Establishment Labs by 187.7% in the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 53,800 shares of the company’s stock worth $3,851,000 after purchasing an additional 35,100 shares in the last quarter. Affinity Asset Advisors LLC raised its stake in Establishment Labs by 29.2% in the 4th quarter. Affinity Asset Advisors LLC now owns 77,500 shares of the company’s stock worth $5,238,000 after purchasing an additional 17,500 shares in the last quarter. Eversept Partners LP acquired a new stake in Establishment Labs in the 4th quarter worth about $1,699,000. Marshall Wace LLP acquired a new stake in Establishment Labs in the 3rd quarter worth about $220,000. Finally, Tudor Investment Corp Et Al raised its stake in Establishment Labs by 227.4% in the 3rd quarter. Tudor Investment Corp Et Al now owns 11,742 shares of the company’s stock worth $840,000 after purchasing an additional 8,156 shares in the last quarter. Institutional investors and hedge funds own 77.79% of the company’s stock.
Establishment Labs Company Profile (Get Rating)
Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander, as well as distributes Puregraft line of products for autologous adipose tissue harvesting and redistribution.
Featured Articles
Receive News & Ratings for Establishment Labs Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Establishment Labs and related companies with MarketBeat.com’s FREE daily email newsletter.
Source: defenseworld.net
